Actavis plan to switch Namenda drug was unlawful, says US court


A US appeals court has ruled that Actavis’s attempt to force Alzheimer’s patients to switch from one medication to another before generic companies entered the market was anti-competitive.

US Court of Appeals for the Second Circuit, Namenda, product hopping, Actavis, Eric Schneiderman, patent